Canada markets closed
  • S&P/TSX

    21,212.39
    +24.20 (+0.11%)
     
  • S&P 500

    4,549.78
    +13.59 (+0.30%)
     
  • DOW

    35,603.08
    -6.26 (-0.02%)
     
  • CAD/USD

    0.8086
    +0.0002 (+0.03%)
     
  • CRUDE OIL

    82.55
    +0.05 (+0.06%)
     
  • BTC-CAD

    77,532.70
    -4,294.34 (-5.25%)
     
  • CMC Crypto 200

    1,490.40
    -44.25 (-2.88%)
     
  • GOLD FUTURES

    1,786.00
    +4.10 (+0.23%)
     
  • RUSSELL 2000

    2,296.18
    +6.42 (+0.28%)
     
  • 10-Yr Bond

    1.6760
    +0.0400 (+2.44%)
     
  • NASDAQ futures

    15,415.00
    -63.75 (-0.41%)
     
  • VOLATILITY

    15.01
    -0.48 (-3.10%)
     
  • FTSE

    7,190.30
    -32.80 (-0.45%)
     
  • NIKKEI 225

    28,669.05
    -39.53 (-0.14%)
     
  • CAD/EUR

    0.6953
    +0.0001 (+0.01%)
     

Solid Biosciences to Participate at Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Carl Morris, Ph.D., Chief Scientific Officer, will participate at the SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic Medicines 1x1 Event and Chardan's 5th Annual Genetic Medicines Conference.

A live webcast of management’s fireside chat at the Chardan conference will be available on the Company’s investor relations website on Tuesday, October 5, 2021 at 2:30 p.m. ET, under the Events page accessible here: https://investors.solidbio.com/news-and-events/events. A replay will be available on the Company's website following the event.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
Caitlin Lowie
Solid Biosciences
607-423-3219
Clowie@solidbio.com

David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting